Analysis of the cardiovascular risk profile in stable kidney transplant recipients after 50% cyclosporine reduction

Clinical Transplantation
Waichi WongManuel Pascual

Abstract

Long-term use of cyclosporine (CsA) contributes to post-transplant cardiovascular disease (CVD). Hence, a reduction in CsA dosage in kidney transplant recipients (KTR) may improve long-term outcomes. We analyzed the effects of 50% CsA dose reduction on the CVD risk profile in stable KTR. Thirty-one KTR on a regimen of CsA, prednisone and mycophenolate mofetil (MMF) were studied. Patients were randomized to either a) continue their previously determined CsA dose (control group, n = 15) or b) lower their CsA dose by 50% (CsA reduction group, n = 16). Renal function, blood pressure, lipid profile, plasma homocysteine (HCY), C-reactive protein (CRP), fibrinogen, and uric acid were compared at baseline and at 6 months. At 6 months, there was a significant improvement in allograft function, systolic blood pressure, number of anti-hypertensive medications and serum uric acid levels in the CsA reduction group. No significant decrease in plasma HCY, CRP, fibrinogen or improvement in lipid profile was found. In contrast, in the Control group, there was a significant increase in HCY, uric acid, and triglycerides. No acute rejection occurred in either group. A greater reduction in CsA dose could further improve CVD risk profiles, although ...Continue Reading

References

Feb 15, 1996·Transplantation·M ArnadottirH Thysell
Oct 1, 1996·Kidney International·W M BennettJ M Barry
Jan 1, 1997·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·A B Irish, F R Green
Nov 18, 1998·Immunology Today·M PascualN Tolkoff-Rubin
Feb 19, 1999·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·R J JohnsonA B Fogo
Apr 13, 1999·Lancet·M D DentonM H Sayegh
Mar 4, 2000·The New England Journal of Medicine·S HariharanD Stablein
Nov 15, 2000·QJM : Monthly Journal of the Association of Physicians·W S WaringS R Maxwell
Jan 12, 2002·Kidney International·Bertram L Kasiske
Feb 22, 2002·The New England Journal of Medicine·Manuel PascualA Benedict Cosimi
Apr 30, 2002·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Jeffrey C FinkMatthew R Weir
May 10, 2002·Pediatric Transplantation·Maria TheirHannu Jalanko
Sep 27, 2002·European Heart Journal·N T MulvihillM Walsh
Oct 22, 2002·JAMA : the Journal of the American Medical Association·Mariska KlerkUNKNOWN MTHFR Studies Collaboration Group
Nov 22, 2002·Journal of the American Society of Nephrology : JASN·Duk-Hee KangRichard J Johnson
Dec 20, 2002·Transplantation·Thomas A GonwaUNKNOWN Sirolimus Renal Function Study Group
Dec 20, 2002·Nature·Peter Libby

❮ Previous
Next ❯

Citations

Oct 21, 2006·Current Opinion in Nephrology and Hypertension·David S Wishart
Jan 16, 2007·Transplantation·Brian M WongG V Ramesh Prasad
Nov 25, 2014·Seminars in Nephrology·Jay I Lakkis, Matthew R Weir
Jan 15, 2014·Transplantation Reviews·Keith A GillisAlan G Jardine
Jun 15, 2010·Transplantation Reviews·Hani M Wadei, Stephen C Textor
Sep 9, 2008·Transplant Immunology·Dela Golshayan, Manuel Pascual
Jul 14, 2006·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Christian PlankJörg Dötsch
Feb 22, 2008·Clinical Journal of the American Society of Nephrology : CJASN·Anushree C Shirali, Margaret J Bia
Dec 19, 2006·Critical Reviews in Clinical Laboratory Sciences·Gian Paolo RossiAchille C Pessina
Jul 17, 2019·Journal of the American Society of Nephrology : JASN·Philip A ClaytonSteven J Chadban
Aug 30, 2008·Drugs in R&D·David S Wishart
Nov 28, 2013·Transplant International : Official Journal of the European Society for Organ Transplantation·Steven J ChadbanUNKNOWN SOCRATES Study Group
Jul 22, 2017·The Cochrane Database of Systematic Reviews·Krishna M KarpeGiles D Walters

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.